KPRX Quote, Financials, Valuation and Earnings

Atossa Therapeutics, Inc. has a net margin of 84.08% compared to Kiora Pharmaceuticals, Inc.'s net margin of --. Kiora Pharmaceuticals, Inc.'s return on equity of -34.44% beat Atossa Therapeutics, Inc.'s return on equity of -47.46%.

Kiora Pharmaceuticals, Inc. has a consensus price target of $11.00, signalling upside risk potential of 411.63%. On the other hand Atossa Therapeutics, Inc. has an analysts' consensus of $5.69 which suggests that it could grow by 648.85%. Given that Atossa Therapeutics, Inc. has higher upside potential than Kiora Pharmaceuticals, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Kiora Pharmaceuticals, Inc..

Kiora Pharmaceuticals, Inc. has a beta of -0.753, which suggesting that the stock is 175.254% less volatile than S&P 500. In comparison Atossa Therapeutics, Inc. has a beta of 0.950, suggesting its less volatile than the S&P 500 by 4.956%.

Kiora Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atossa Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiora Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Atossa Therapeutics, Inc. pays out -- of its earnings as a dividend.

Kiora Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Atossa Therapeutics, Inc. quarterly revenues of --. Kiora Pharmaceuticals, Inc.'s net income of $26.8K is higher than Atossa Therapeutics, Inc.'s net income of -$8.7M. Notably, Kiora Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Atossa Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiora Pharmaceuticals, Inc. is -- versus -- for Atossa Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Celldex Therapeutics, Inc. has a net margin of 84.08% compared to Kiora Pharmaceuticals, Inc.'s net margin of -7753.43%. Kiora Pharmaceuticals, Inc.'s return on equity of -34.44% beat Celldex Therapeutics, Inc.'s return on equity of -32.17%.

Kiora Pharmaceuticals, Inc. has a consensus price target of $11.00, signalling upside risk potential of 411.63%. On the other hand Celldex Therapeutics, Inc. has an analysts' consensus of $53.14 which suggests that it could grow by 79.54%. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Celldex Therapeutics, Inc., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Celldex Therapeutics, Inc..

Kiora Pharmaceuticals, Inc. has a beta of -0.753, which suggesting that the stock is 175.254% less volatile than S&P 500. In comparison Celldex Therapeutics, Inc. has a beta of 1.133, suggesting its more volatile than the S&P 500 by 13.281%.

Kiora Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celldex Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiora Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Celldex Therapeutics, Inc. pays out -- of its earnings as a dividend.

Kiora Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Celldex Therapeutics, Inc. quarterly revenues of --. Kiora Pharmaceuticals, Inc.'s net income of $26.8K is higher than Celldex Therapeutics, Inc.'s net income of -$67M. Notably, Kiora Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Celldex Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiora Pharmaceuticals, Inc. is -- versus 755.79x for Celldex Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics, Inc. has a net margin of 84.08% compared to Kiora Pharmaceuticals, Inc.'s net margin of -735.19%. Kiora Pharmaceuticals, Inc.'s return on equity of -34.44% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.

Kiora Pharmaceuticals, Inc. has a consensus price target of $11.00, signalling upside risk potential of 411.63%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $24.85 which suggests that it could grow by 130.31%. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Intellia Therapeutics, Inc., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Intellia Therapeutics, Inc..

Kiora Pharmaceuticals, Inc. has a beta of -0.753, which suggesting that the stock is 175.254% less volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.133, suggesting its more volatile than the S&P 500 by 113.344%.

Kiora Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiora Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Kiora Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Kiora Pharmaceuticals, Inc.'s net income of $26.8K is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Kiora Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiora Pharmaceuticals, Inc. is -- versus 17.75x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of 84.08% compared to Kiora Pharmaceuticals, Inc.'s net margin of 7.29%. Kiora Pharmaceuticals, Inc.'s return on equity of -34.44% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

Kiora Pharmaceuticals, Inc. has a consensus price target of $11.00, signalling upside risk potential of 411.63%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 5.47%. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Phibro Animal Health Corp..

Kiora Pharmaceuticals, Inc. has a beta of -0.753, which suggesting that the stock is 175.254% less volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

Kiora Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.18% to investors and pays a quarterly dividend of $0.12 per share. Kiora Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Kiora Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. Kiora Pharmaceuticals, Inc.'s net income of $26.8K is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Kiora Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Phibro Animal Health Corp.'s PE ratio is 24.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiora Pharmaceuticals, Inc. is -- versus 1.19x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.